PTM Therapeutics is focused on developing antibody therapeutics targeting post-translational modifications including glycans. Its primary asset, PTM-001 is being developed for the treatment of Inflammatory Bowel Disease (IBD). Unlike existing IBD therapies PTM-001 does not directly target the immune system but instead, promotes intestinal mucosal wound healing and has demonstrated promising efficacy in in vivo IBD models.
Location: United States, California, San Mateo
Investors 3
| Date | Name | Website |
| 18.11.2020 | BioRock Ve... | biorockven... |
| - | Biobrit | biobrit.co... |
| - | MBC BioLab... | mbcbiolabs... |